Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium.

Lancaster, Kathryn E; Stockton, Melissa; Remch, Molly; Wester, C William; Nash, Denis; Brazier, Ellen; Adedimeji, Adebola; Finlayson, Robert; Freeman, Aimee; Hogan, Breanna; Kasozi, Charles; Kwobah, Edith Kamaru; Kulzer, Jayne Lewis; Merati, Tuti; Tine, Judiacel; Poda, Armel; Succi, Regina; Twizere, Christelle; Tlali, Mpho; von Groote, Per Maximilian; ... (2024). Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium. International journal of drug policy, 124, p. 104309. Elsevier 10.1016/j.drugpo.2023.104309

Preview

Text 1-s2.0-S0955395923003560-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (752kB) | Preview

BACKGROUND

Overwhelming evidence highlights the negative impact of substance use on HIV care and treatment outcomes. Yet, the extent to which alcohol use disorder (AUD) and other substance use disorders (SUD) services have been integrated within HIV clinical settings is limited. We describe AUD/SUD screening and treatment availability in HIV clinical sites participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium.

METHODS

In 2020, 223 IeDEA HIV clinical sites from 41 countries across seven geographic regions completed a survey on capacity and practices related to management of AUD/ SUD. Sites provided information on AUD and other SUD screening and treatment practices.

RESULTS

Sites were from low-income countries (23%), lower-middle-income countries (38%), upper-middle income countries (17%) and high-income counties (23%). AUD and SUD screening using validated instruments were reported at 32% (n=71 located in 12 countries) and 12% (n=27 located in 6 countries) of the 223 sites from 41 countries, respectively. The North American region had the highest proportion of clinics that reported AUD screening (76%), followed by East Africa (46%); none of the sites in West or Central Africa reported AUD screening. 31% (n=69) reported both AUD screening and counseling, brief intervention, psychotherapy, or Screening, Brief Intervention, and Referral to Treatment; 8% (n=18) reported AUD screening and detox hospitalization; and 10% (n=24) reported both AUD screening and medication. While the proportion of clinics providing treatment for SUD was lower than those treating AUD, the prevalence estimates of treatment availability were similar.

CONCLUSIONS

Availability of screening and treatment for AUD/SUD in HIV care settings is limited, leaving a substantial gap for integration into ongoing HIV care. A critical understanding is needed of the multilevel implementation factors or feasible implementation strategies for integrating screening and treatment of AUD/SUD into HIV care settings, particularly for resource-constrained regions.

Interest & Impact

Downloads

2 since deposited on 17 Jan 2024
2 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item